Ligand Pharmaceuticals (NAS:LGND) Sale Of Business

: $0.0 Mil (TTM As of Dec. 2022)

View and export this data going back to 1995. Start your Free Trial

Ligand Pharmaceuticals's sale of business for the three months ended in Dec. 2022 was $0.0 Mil. It means Ligand Pharmaceuticals gained $0.0 Mil from selling business. Ligand Pharmaceuticals's sale of business for the trailing twelve months (TTM) ended in Dec. 2022 was $0.0 Mil.

Compared with last quarter ($0.0 Mil in Sep. 2022 ), Ligand Pharmaceuticals gained the same money from selling business in Dec. 2022 ($0.0 Mil).

Ligand Pharmaceuticals Sale Of Business Historical Data

The historical data trend for Ligand Pharmaceuticals's Sale Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ligand Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Sale Of Business

22.06

Ligand Pharmaceuticals Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Sale Of Business																-	-	-	-	-

Ligand Pharmaceuticals Sale Of Business Calculation

The amount earned to sell business.

Sale Of Business for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

Ligand Pharmaceuticals Sale Of Business Related Terms

Thank you for viewing the detailed overview of Ligand Pharmaceuticals's Sale Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.

Ligand Pharmaceuticals (NAS:LGND) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ligand Pharmaceuticals Inc (NAS:LGND) » Definitions » Sale Of Business

Comparable Companies

Traded in Other Exchanges

LGDN:Germany

Address

5980 Horton Street, Suite 405, Emeryville, CA, USA, 94608

Website

https://www.ligand.com

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Executives

Stephen L Sabba	director	DORSET MANAGEMENT CORP, 485 UNDERHILL BLVD SUITE 205, SYOSSET NY 11791
Andrew Reardon	officer: See Remarks	C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121
Octavio Espinoza	officer: Chief Financial Officer	C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 110, SAN DIEGO CA 92121
Jason Haas	director	C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Jennifer R. Cochran	director	C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 100, SAN DIEGO CA 92121
Goldman Sachs Group Inc	10 percent owner	200 WEST STREET, NEW YORK NY 10282
Goldman Sachs & Co. Llc	10 percent owner	200 WEST STREET, NEW YORK NY 10282
Sarah Boyce	director	C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Nancy Ryan Gray	director	C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BOULEVARD, STE 110, SAN DIEGO CA 92121
Matthew E Korenberg	officer: VP, Finance and CFO	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Melanie J Herman	officer: Director of Accounting	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Investment 10 Llc	other: See Explanation of Responses	C/O GROSVENOR CAPITAL MANAGEMENT LP, 900 N. MICHIGAN AVENUE, SUITE 1100, CHICAGO IL 60611
Nishan M Desilva	officer: VP, Corporate Development	11119 NORTH TORREY PINES RD STE 200, LA JOLLA CA 92037
Matthew W Foehr	officer: EVP and COO	11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037
John L Lamattina	director	81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454